A new experimental pill may soon change how doctors treat high cholesterol and prevent heart disease.
In a large clinical study published in The New England Journal of Medicine, researchers found that a drug called enlicitide can lower levels of low-density lipoprotein, or LDL cholesterol, by up to 60 percent.
LDL cholesterol is often called “bad” cholesterol because high levels can damage blood vessels and increase the risk of heart attacks and strokes.
Heart disease is one of the leading causes of death worldwide. A major reason is the buildup of cholesterol inside the walls of arteries. Over time, this buildup forms plaques that narrow the arteries and reduce blood flow.
This process is called atherosclerosis. If a plaque breaks, it can block blood flow completely, leading to a heart attack or stroke. Because of this, lowering LDL cholesterol has been one of the most important goals in medicine for many years.
For decades, doctors have used drugs called statins to lower cholesterol. Statins work by reducing the amount of cholesterol the liver produces. They have helped millions of people and remain the most commonly used treatment today.
However, many patients still do not reach their target cholesterol levels, even when taking strong statins. This leaves them at continued risk of serious heart problems.
The development of enlicitide builds on many years of scientific research. In the 1980s, scientists discovered special receptors in the liver that remove LDL cholesterol from the blood.
This discovery later won the Nobel Prize and helped lead to modern cholesterol treatments. More recently, researchers found that a protein called PCSK9 can reduce the number of these receptors, making it harder for the body to clear cholesterol.
This discovery led to the creation of PCSK9 inhibitor drugs, which are very effective at lowering cholesterol. These drugs can reduce LDL levels by about 60 percent. However, they are usually given as injections, which makes them less convenient. Many patients and doctors are less willing to use injectable treatments, even when they work well.
Enlicitide works by targeting the same PCSK9 pathway, but it comes in the form of a daily pill. This makes it much easier to use. Instead of injections every few weeks, patients can simply take a tablet each day, which could improve long-term treatment and patient comfort.
The recent phase three clinical trial included nearly 3,000 people. These participants either already had atherosclerosis or were at high risk of developing it. Most of them were already taking statins, but their cholesterol levels were still higher than recommended.
On average, their LDL levels were around 96 milligrams per deciliter, which is above the target levels suggested by guidelines.
After 24 weeks of treatment, those who took enlicitide saw their LDL cholesterol drop by about 60 percent compared to those who received a placebo. This is a very large reduction and is similar to what injectable PCSK9 drugs can achieve.
The study also showed improvements in other important markers linked to heart disease, such as apolipoprotein B and lipoprotein(a). These benefits continued for up to one year.
The lead researcher, Dr. Ann Marie Navar, explained that fewer than half of patients with existing heart disease reach their cholesterol goals with current treatments. She suggested that a simple and effective pill like enlicitide could help many more people reduce their risk of heart attacks and strokes.
However, while these results are very promising, there are still important questions to answer. Lowering cholesterol is known to reduce heart risk, but researchers still need to confirm that this new drug will actually lead to fewer heart attacks and strokes in real-world patients. A larger study is already underway to examine these long-term outcomes.
Another point to consider is safety and cost. New medications can sometimes have unexpected side effects, and pricing can affect how widely they are used. It will be important to monitor these factors if the drug is approved.
Overall, this study represents an exciting step forward in heart health. It offers a new option that combines strong effectiveness with the convenience of a daily pill. If future studies confirm its benefits, enlicitide could become an important tool in preventing heart disease.
In conclusion, the findings show that enlicitide can greatly reduce LDL cholesterol levels, which is a key factor in heart disease. The strength of the study lies in its large size and realistic patient group.
However, more research is needed to confirm long-term benefits and safety. If successful, this drug could help close the gap for patients who cannot reach their cholesterol goals with current treatments.
If you care about health, please read studies about the benefits of low-dose lithium supplements, and what we know about egg intake and heart disease.
For more health information, please see recent studies about potatoes and high blood pressure, and results showing 6 best breads for people with heart disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
